Baseline Assessment of Serum Cytokines Predicts Clinical and Endoscopic Response to Ustekinumab in Patients With Crohn’s Disease: A Prospective Pilot Study
Inflammatory Bowel Diseases · 2024
DOI: 10.1093/ibd/izae133 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2024. Verfasst von Lorenzo Bertani und 15 weiteren Autor:innen. Beteiligte Einrichtung: University of Pisa, Department of Translational Research and New Technologies in Medicine and Surgery, Via Roma, 67, 56100 Pisa, Italy. Hauptthemen laut MEDLINE: Ustekinumab, Crohn Disease, Leukocyte L1 Antigen Complex, Biomarkers. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Janssen Biotech spa.
Abstract (Originalsprache)
Background
No biomarkers are currently available to predict therapeutic response to ustekinumab (UST) in Crohn’s disease (CD). The aim of this prospective study was to identify 1 or more cytokines able to predict mucosal healing in patients with CD treated with UST.
Methods
We prospectively enrolled consecutive CD patients treated with UST. At weeks 0 (baseline), 24, and 48, a panel of serum cytokines was measured by a fluorescence assay. At the same time points, fecal calprotectin (FC) was assessed. A colonoscopy was performed at baseline and at week 48, where therapeutic outcome was evaluated in terms of mucosal healing.
Results
Out of 44 patients enrolled, 22 (50%) achieved mucosal healing at the end of follow-up. Response was associated with higher interleukin (IL)-23 levels (P < .01). Fecal calprotectin levels decreased over time in responders but did not change in nonresponders (test for the interaction between time and mucosal healing, P < .001).
Conclusions
This pilot study showed that IL-23 and FC could be reliable biomarkers in predicting therapeutic outcome to UST therapy in CD. In particular, the correlation between baseline serum levels of IL-23 and mucosal healing at 48 weeks is particularly strong, paving the way for its use to drive therapeutic decisions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Pisa, Department of Translational Research and New Technologies in Medicine and Surgery, Via Roma, 67, 56100 Pisa, Italy.
- Tuscany North West ASL, Department of General Surgery and Gastroenterology, Pontedera Hospital, Via Roma, 147, 56025, Pontedera, Italy.
- University of Pisa, Department of Clinical and Experimental Medicine, Via Roma, 67, 56100, Pisa, Italy.
- Pisa University Hospital, IBD Unit, Department of General Surgery and Gastroenterology, Via Paradisa, 2, 56124, Pisa, Italy.
ORCID-Profile: Lorenzo Bertani
Förderung
- Janssen Biotech spa
Zitieren
APA
Bertani, L., Antonioli, L., Fornili, M., D'Antongiovanni, V., Ceccarelli, L., Carmisciano, L., Benvenuti, L., Mumolo, M. G., Bottari, A., Pardi, V., Baiano Svizzero, G., Baglietto, L., De Bortoli, N., Bellini, M., Fornai, M., & Costa, F. (2024). Baseline Assessment of Serum Cytokines Predicts Clinical and Endoscopic Response to Ustekinumab in Patients With Crohn’s Disease: A Prospective Pilot Study. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izae133
Vancouver
Bertani L, Antonioli L, Fornili M, D'Antongiovanni V, Ceccarelli L, Carmisciano L, et al. Baseline Assessment of Serum Cytokines Predicts Clinical and Endoscopic Response to Ustekinumab in Patients With Crohn’s Disease: A Prospective Pilot Study. Inflammatory Bowel Diseases. 2024. doi:10.1093/ibd/izae133
BibTeX
@article{Bertani2024,
author = {Bertani, Lorenzo and Antonioli, Luca and Fornili, Marco and D'Antongiovanni, Vanessa and Ceccarelli, Linda and Carmisciano, Luca and Benvenuti, Laura and Mumolo, Maria Gloria and Bottari, Andrea and Pardi, Veronica and Baiano Svizzero, Giovanni and Baglietto, Laura and De Bortoli, Nicola and Bellini, Massimo and Fornai, Matteo and Costa, Francesco},
title = {Baseline Assessment of Serum Cytokines Predicts Clinical and Endoscopic Response to Ustekinumab in Patients With Crohn’s Disease: A Prospective Pilot Study},
journal = {Inflammatory Bowel Diseases},
year = {2024},
doi = {10.1093/ibd/izae133}
}
EUVIMED